A Ovid Therapeutics e a Angelini Pharma celebram um acordo de licença exclusivo para desenvolver, fabricar e comercializar o medicamento OV101 para o tratamento da síndrome de Angelman na Europa
July 14, 2020 18:01 ET
|
Ovid Therapeutics Inc.
A Angelini Pharma obtém os direitos exclusivos de desenvolvimento, fabricação e comercialização do OV101 (gaboxadol) para o potencial tratamento da síndrome de Angelman na União Europeia, outros...
Ovid Therapeutics, 유럽 내 엔젤만증후군 치료용 OV101의 개발, 생산, 상용화 위해 Angelini Pharma와 독점 라이선스 계약 체결
July 14, 2020 18:01 ET
|
Ovid Therapeutics Inc.
Angelini Pharma는 유럽연합 및 기타 유럽경제지역 국가(스위스, 터키, 영국), 그리고 러시아에 공급될 수 있는 엔젤만증후군 치료용 OV101 (gaboxadol)의 독점적인 개발, 생산, 상용화 권한 획득Ovid Therapeutics에게는 2,000만 달러를 선급금으로 지급됨, 향후 초기 적응증(엔젤만증후군)과 관련된 개발과 생산, 판매 성과...
オービッド･セラピューティクスとアンジェリーニ･ファーマ、アンジェルマン症候群の治療薬としてのOV101のヨーロッパにおける開発、製造、商品化に関する独占ライセンス契約を締結
July 14, 2020 18:01 ET
|
Ovid Therapeutics Inc.
アンジェリーニ･ファーマは、EU、欧州経済地域諸国、およびスイス、トルコ、英国、ロシアにおいて、アンジェルマン症候群への治療効果を期待できるOV101 (ガボキサドール) の開発、製造、商品化の独占的な権利を取得オービッド･セラピューティクスは、前払い金の2,000万ドル (約21億4,000万円) に加え、開発、製造、販売のマイルストーンを達成した段階で最大2億1,250万ドル...
Ovid Therapeutics et Angelini Pharma concluent un accord de licence exclusif concernant le développement, la fabrication et la commercialisation d'OV101 pour le traitement du syndrome d'Angelman en Europe
July 14, 2020 18:01 ET
|
Ovid Therapeutics Inc.
Angelini Pharma obtient les droits exclusifs de développement, de fabrication et de commercialisation d'OV101 (gaboxadol) pour le traitement potentiel du syndrome d'Angelman dans l'Union européenne et...
Ovid Therapeutics 與 Angelini Pharma 簽訂獨家許可協議以開發、生產和商業化 OV101，以治療歐洲的天使綜合症
July 14, 2020 18:01 ET
|
Ovid Therapeutics Inc.
Angelini Pharma 獲得 OV101 (gaboxadol) 的獨家開發、生產和商業化權利，以治療歐盟和歐洲經濟區其他國家，及瑞士、土耳其、英國和俄羅斯的天使綜合症 如可成功實現開發、生產和銷售的里程碑，Ovid Therapeutics 將獲得 2,000 萬美元的首期付款和高達 2.125 億美元的額外付款，並在成功實現商業化後按淨銷售額獲得雙位數字的特許權使用費 Angelini...
Ovid Therapeutics和Angelini Pharma签订开发、生产和商业化独家许可协议以利用OV101在欧洲治疗天使综合征
July 14, 2020 18:01 ET
|
Ovid Therapeutics Inc.
Angelini Pharma获得OV101（gaboxadol）开发、生产和商业化独家权利，用于欧盟、欧洲经济区其他国家以及瑞士、土耳其、英国和俄罗斯天使综合征患者的潜在治疗 Ovid Therapeutics将获得2000万美元前期付款并将在实现开发、制造和销售里程碑后再获得高达2.125亿美元的付款；此外如成功实现商业化还将获得净销售额两位数百分比的特许权收入 Angelini...
Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe
July 13, 2020 07:00 ET
|
Ovid Therapeutics Inc.
Angelini Pharma obtains exclusive development, manufacturing and commercialization rights to OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the European Union and other...
Ovid Therapeutics Added to Russell 2000® and Russell 3000® Indexes
June 29, 2020 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome
June 19, 2020 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, June 19, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
Ovid Therapeutics Announces Strategic Research Collaboration Focused on Accelerating the Development of New Treatments for Rare Neurological Diseases
June 11, 2020 08:00 ET
|
Ovid Therapeutics Inc.
Broad multiyear alliance with Columbia University Irving Medical Center researchers to focus on development of potential medicines using genetic based therapies and create a therapeutic platform for a...